ICO Iconovo AB (publ)
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Iconovo (STO: ICO)
›
Iconovo (STO: ICO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.020 SEK on 19 November 2026, down 40.5% over 52 weeks. Its 52-week range is 0.8700 SEK to 1.740 SEK: the price is 41.4% below the high and 17.2% above the low.
Its market capitalisation is 98.10M SEK.
Iconovo reports return on equity of -36.8%.
It holds more cash than debt, a net cash position of 22.88M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.8500 SEK is 16.7% below the current price.